Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
GABRA6 antisense RNA 1 (GABRA6-AS1)
- Target
- GABRA6-AS1
- Molecular classification
- Long non-coding RNA (lncRNA), antisense RNA
01
Overview
GABRA6 antisense RNA 1 is a long non-coding RNA gene located on chromosome 5 that overlaps with the sense strand encoding GABA receptor subunit alpha-6 (GABRA6). This lncRNA (also called ARBAG) regulates the stability and expression of GABRA6 mRNA, influencing the ratio of mRNA isoforms and affecting protein functionality. The variant rs4454083 within ARBAG alters its abundance in the cerebellum and is associated with plasma C-peptide levels, implicating a role in insulin bioavailability. Increased ARBAG expression leads to the destabilization and cleavage of GABRA6 mRNA, which can result in dysfunctional GABA-A receptor subunit and altered synaptic regulation. Its function thus primarily lies in gene regulation rather than direct pharmacological targeting[3][5][7][10].
- Other names
- ARBAGGABRA6-AS1
02
Mechanism of action
N/A; no drug mechanisms targeting this molecule reported
03
Biological functions
Regulation of gene expression (specifically controls the expression and stability of GABRA6 mRNA)Modulation of synaptic function (indirectly, through GABRA6)Potential involvement in regulation of insulin signaling (via C-peptide)
04
Disease associations
May be associated with neuropsychiatric disorders through GABRA6 modulationPossible link to metabolic traits by regulating C-peptide and insulin bioavailabilityNo direct evidence for roles in cancer, inflammation, neurodegenerative disease, or infection found in current sources
05
Safety considerations
None reported; as it is not directly targeted by drugs, safety concerns are limited to potential gene regulation effects that might impact GABRA6 function
06
Biomarkers
Associated variant rs4454083 affects C-peptide levels; possible implication as a biomarker for insulin bioavailability
Beyond the preview
Go deeper on GABRA6 antisense RNA 1 (GABRA6-AS1).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GABRA6 antisense RNA 1 (GABRA6-AS1).